Recommended Topic Related To:


"The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved t"...



The expected manifestations of Mircera (methoxy polyethylene glycol-epoetin beta) overdosage include signs and symptoms associated with an excessive and/or rapid increase in hemoglobin concentration, including any of the cardiovascular events described above [see Warnings and PRECAUTIONS] and [ADVERSE REACTIONS]. Patients receiving an overdosage of Mircera (methoxy polyethylene glycol-epoetin beta) should be monitored closely for cardiovascular events and hematologic abnormalities. Polycythemia should be managed acutely with phlebotomy, as clinically indicated. Following resolution of the effects due to Mircera (methoxy polyethylene glycol-epoetin beta) overdosage, reintroduction of Mircera (methoxy polyethylene glycol-epoetin beta) therapy should be accompanied by close monitoring for evidence of rapid increases in hemoglobin concentration ( > 1 g/dL per 14 days). In patients with an excessive hematopoietic response, reduce the Mircera (methoxy polyethylene glycol-epoetin beta) dose in accordance with the recommendations described in DOSAGE AND ADMINISTRATION.


Mircera (methoxy polyethylene glycol-epoetin beta) is contraindicated in patients with uncontrolled hypertension [see Warnings and PRECAUTIONS].

Mircera (methoxy polyethylene glycol-epoetin beta) is contradicted in patients with a history of hypersensitivity or allergy to the drug [see Warnings and PRECAUTIONS].

Last reviewed on RxList: 12/20/2007
This monograph has been modified to include the generic and brand name in many instances.


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options.